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ABSTRACT
Recent studies have shown that in response to vascular damage or ischemia, bone marrow-derived
endothelial progenitor cells (EPCs) are recruited into the circulation. To investigate whether anti-
hypertensive treatment has an influence on the number of circulating EPCs, patients with essential
hypertension were treated either with the angiotensin receptor antagonist telmisartan, the calcium
channel blocker nisoldipine, or their combination for 6 weeks. At baseline and after 3 and 6 weeks
of treatment, EPCs were identified and quantified by fluorescence-activated cell sorting (FACS)
analysis and by their capacity to generate colony-forming units of the endothelial lineage (CFU-EC)
in a methylcellulose-based assay. During treatment, patients in the nisoldipine groups, but not in
the telmisartan group, showed a significant mobilization of EPCs, which in part had the capacity
to generate large-sized colonies comprising more than 1,000 cells. Moreover, a remarkable correla-
tion between the number of CFU-EC and the number of circulating CD133/CD34/CD146 cells
was observed, thereby providing strong evidence that cells with this phenotype represent functional
EPCs. No correlation was found between the numbers of CFU-EC and the blood pressure levels at
any time point during the treatment. Hence, nisoldipine-induced mobilization of EPCs might rep-
resent a novel mechanism by which this antihypertensive compound independently of its blood pres-
sure-lowering effect contributes to vasoprotection in patients with essential hypertension.
329
INTRODUCTION
ADULT BONE MARROW contains a variety of hematopoi-etic and nonhematopoietic stem and progenitor cells,
among which a scarce population of endothelial progenitor
cells (EPCs) exists. These precursors are characterized by
expression of the stem cell markers CD34, CD133, and vas-
cular endothelial growth factor receptor-2 (VEGFR-2)
(1,2). Because CD34 and VEGFR-2 are also expressed on
mature endothelium, CD133 is currently the only marker
to distinguish EPCs from differentiated endothelial cells,
from which it is absent (3–5). Nevertheless, identification
of EPCs is still complicated by the fact that all three mark-
ers mentioned can also be found on hematopoietic stem
cells (5–8). Thus, further phenotypic characterization is
needed for the discrimination between EPCs and hemato-
poietic precursors. Co-expression studies, including surface
molecules that are expressed on mature endothelial cells
but not on mature hematopoietic cells, provide a useful ap-
proach in this context. However, endothelial cells and he-
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matopoietic cells share expression of several antigens, mak-
ing it difficult to find an endothelial-specific marker. The
cell adhesion molecule CD146 (Endo-1 or P1H12), al-
though not exclusively expressed on endothelial cells,
might represent a suitable marker to define further the phe-
notype of EPCs because it is not expressed on hematopoi-
etic cells (9). Besides phenotypical analysis, EPCs can be
indirectly identified by their capacity to form colonies in
vitro (1,10,11).
Under steady-state conditions, EPCs represent less
than 0.01% of the cells in the circulation, but their number
can significantly increase in pathological situations, such
as vascular or myocardial injury, early stages of heart
failure, and malignant diseases (12–15). Furthermore,
EPCs can be mobilized from the bone marrow into the
circulation by a variety of growth factors, chemokines,
hormones, and drugs, including VEGF, granulocyte-mac-
rophage colony-stimulating factor (GM-CSF), estrogen,
and statins and subsequently promote neovascularization
in ischemic organs or contribute to (re)endothelializa-
tion of implanted vascular grafts or denuded arteries
(1,16–20). It has therefore been hypothesized that EPCs
may play a crucial role in maintaining the integrity of the
vascular endothelial monolayer (21).
Hypertension is a highly prevalent risk factor of cardio-
vascular disease, which is accompanied by alterations of
the endothelium and structure of the vascular system (22).
Moreover, hypertension is commonly associated with in-
creased levels of angiotensin II, the main effector peptide
of the renin angiotensin system, which has been reported
to induce EPC proliferation and network formation (23).
Although the role of EPCs in vascular biology has been
studied extensively, their role and function in hypertension
is yet undefined. In this context, the effect of antihyper-
tensive drugs, e.g., angiotensin receptor antagonists or cal-
cium channel blockers, on mobilization of EPCs in patients
with essential hypertension has not been examined so far.
Therefore, we performed a clinical study to investigate the
effect of the angiotensin receptor antagonist telmisartan, the
calcium channel blocker nisoldipine, and their combination
on the number of circulating EPCs in patients with essen-
tial hypertension.
In this study, we provide evidence that treatment of
hypertensive patients with nisoldipine leads to mobiliza-
tion of EPCs, which in part exhibit exceptional clono-
genic capacity and are characterized by a CD133/
CD34/CD146 phenotype.
MATERIALS AND METHODS
Patients and study protocol
The study comprised 37 patients with essential hyper-
tension and was performed as a single-center, random-
ized, blinded study. The study was approved by the lo-
cal Ethics Committee and conducted according to the
principles of Good Clinical Practice and the Declaration
of Helsinki. Patients were eligible for the study if they
had been diagnosed with essential hypertension (i.e., ex-
clusion of other etiologies of hypertensive disease), were
between 20 and 80 years old, and had signed the informed
consent form. Important exclusion criteria were treatment
with statins or hormones (estrogens, gestagens), liver or
renal dysfunction, severe heart failure, diabetes mellitus,
acute or unstable coronary artery disease, or previously
experienced hyperreactivity against angiotensin receptor
antagonists or calcium channel blockers. Patients who
were on continuous antihypertensive treatment under-
went a wash-out phase of all antihypertensive and va-
soactive medication during 2 weeks prior to study entry.
During this period, clonidine and hydrochlorothiazide
were available as rescue medication in the event that
blood pressure reached a level of 180/110 mmHg.
Baseline examination at day 1 of the study included
peripheral blood analysis, physical examination, and a
24-h automated ambulatory blood pressure monitoring.
Study medication was started at day 2 and was either
telmisartan 40 mg orally per day, nisoldipine 10 mg orally
per day, or a combination of telmisartan 40 mg plus nisol-
dipine 10 mg orally per day for 3 weeks. Evaluation at
day 21 comprised peripheral blood analysis and 24-h am-
bulatory blood pressure monitoring. At this time, the
daily dose of the study medication was increased to 80
mg in the telmisartan group, to 20 mg in the nisoldipine
group, and to 80/10 mg for the combined therapy with
telmisartan/nisoldipine; this dosage was given for the fol-
lowing 3 weeks. The final examination at day 42 again
consisted of peripheral blood analysis and 24-h ambula-
tory blood pressure monitoring. Thereafter, the initial an-
tihypertensive regimen was restarted and patients were
supervised until their blood pressure had reached levels
similar to those before study entry.
Preparation of peripheral blood samples
Heparinized blood samples obtained from patients at
baseline, day 21, and day 42 were incubated with he-
molytic buffer (0.155 mol/L NH4Cl, 0.012 mol/L
NaHCO3, 0.1 mmol/L EDTA, pH 7.2) for 5 and 2 min
and immediately prepared for fluorescence-activated cell
sorting (FACS) analysis and colony assays.
Flow cytometry analysis
After washing in phosphate-buffered saline (PBS)
containing 0.1% bovine serum albumin (BSA), 1  106
cells per tube were incubated with phycoerythrin (PE)-
conjugated anti-CD133 monoclonal antibody (mAb;
clone AC141, Miltenyi Biotec, Bergisch Gladbach,
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Germany) in combination with either fluorescein 
isothiocyanate (FITC)-conjugated anti-CD34 mAb
(Anti-HPCA-2, BD Pharmingen, Hamburg, Germany), 
anti-CD45 mAb, anti-CD14 mAb (all from BD
Pharmingen), or anti-von Willebrand Factor (vWF;
Serotec, Düsseldorf, Germany). Other combinations in-
cluded PE-anti-CD144 mAb (Coulter-Immunotech,
Krefeld, Germany) with either FITC-anti-CD34 or
FITC-anti-vWF, or PE-anti-CD146 (Coulter-Im-
munotech) with either FITC-anti-CD34 or FITC-anti-
vWF. Isotype-matched anti-immunoglobulins mABs
(BD Pharmingen) served as controls. All incubations
were performed at 4°C in the presence of normal goat
serum. For expression studies including vWF, cells
were fixed and permeabilized (Intrastain Kit, Dako Cy-
tomation, Hamburg) before incubation with anti-vWF
mAb. Two-color flow cytometry was accomplished us-
ing a FACS Calibur flow cytometer (Becton Dickin-
son, Heidelberg, Germany) and Cell Quest software
(Becton Dickinson) as previously described (2). Each
analysis included at least 50,000 events.
Clonogenic assay for EPCs
Remaining peripheral blood cells were plated at 1  105
cells/ml in methylcellulose (Stem Cell Technologies, St.
Katharinen, Germany), as previously described (2).
Briefly, cells were cultured in methylcellulose that was
supplemented with stem cell growth factor (SCGF; 100
ng/ml, TEBU, Frankfurt, Germany) and VEGF (50 ng/ml,
TEBU). All cultures were performed in quadruplicate, in-
cubated at 37°C in 5% CO2 and 95% humidity, and scored
after 14 days using an inverted microscope.
Statistical analysis
Distribution of data was tested with the Kolmogorov–
Smirnov test. Continuous variables were expressed as
arithmetic mean  standard deviation (SD) if normally
distributed or otherwise as median with 25% and 75% per-
centiles (IQR). Differences in baseline characteristics
among groups were tested with one-way analysis of vari-
ance (ANOVA) if normally distributed, while baseline dif-
ferences of variables with skewed distribution were tested
with the Kruskal–Wallis H or Mann–Whitney U test.
Changes during treatment within different treatment
groups were tested either with repeated-measure ANOVA
followed by the paired t-test, the nonparametric test of re-
peated measures on ranks (Friedman test) followed by
Wilcoxon’s test, or with Wilcoxon’s test alone. Bivariate
correlations were analyzed using Spearman’s rho. Proba-
bility values 0.05 were considered significant. For all
statistical analysis, SPSS version 12.0 was used.
RESULTS
Patients’ characteristics
Baseline characteristics of the hypertensive patients
studied are shown in Table 1. Treatment groups did not
significantly differ in age, gender, mean blood pressure,
or washout medication, but patients randomized to receive
nisoldipine had a significantly higher body mass index
(BMI) as compared to patients who had been randomized
to telmisartan treatment (27.1  4.1 vs. 23.0  3.0; p 
0.05). Except for this observation, baseline characteristics
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TABLE 1. PATIENT CHARACTERISTICS
Telmisartan Nisoldipine Combination
(n  12) (n  13) (n  12) P
Gender (male/female) 7/5 6/7 7/5 ns.
Age (years) 59.0  7 56.9  8 59.6  8 ns.
Mean blood pressure (mmHg) 103.6  8.7 108.6  12.5 99.8  7.5 ns.
Body-mass index (kg/m2) 23.0  3.0* 27.1  4.1* 24.5  4.2 *0.043
Cholesterol (mg/dL) 244  32 236  48 254  46 ns.
HDL (mg/dL) 63  13 56  11 58  16 ns.
LDL (mg/dL) 158  25 150  41 164  28 ns.
C-reactive protein high 0.95 (0.7-1.925) 2.1 (1.25-3.7) 1.9 (1.125-3.15) ns.
sensitive (mg/L)
Creatinine (mg/dL) 0.95  0.17 0.95  0.15 0.93  18 ns.
Fasting glucose (mmol/dL) 5.1  0.6 5.4  0.4 5.4  0.7 ns.
Current Smokers 0 1 1 ns.
Wash-out medication:
Hydrochlorothiazide 6 8 7 ns.
Clonidine 2 2 1 ns.
Data are given as mean  SD (parametric data) or median with interquartile range (non-parametric data). n.s.; not significant.
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CD133 and CD34 cells. Additionally, blood cells
were transferred to a methylcellulose-based assay,
which has been shown to specifically induce formation
of endothelial colonies (referred to as CFU-EC) from
granulocyte colony-stimulating factor (G-CSF) mobi-
lized CD133/CD34 EPCs (2). In this assay, periph-
eral blood cells from healthy controls only rarely give
rise to single colonies, according to the finding that the
mononuclear cell fraction from peripheral blood of
healthy donors contains less than 0.01% CD133 en-
dothelial progenitor cells (12–15). As observed for the
number of circulating CD133/CD34 cells (Fig. 1A),
the absolute number of colony-forming units–endothe-
lial (CFU-EC) at baseline in patients randomized to
nisoldipine treatment was significantly higher than
those obtained in the combination group [median 1
(range 0–8) vs. 0 (0–2), p  0.05; Fig. 1B], but was not
significantly different from the levels noted in the
telmisartan group [2 (0–2)]. During treatment, a signif-
icant increase in the number of CFU-EC was found at
day 21 in patients who received nisoldipine (mono and
combination therapy) but not in patients treated with
telmisartan alone [nisoldipine: 12 (1–24), p  0.01 vs.
baseline; combination: 2 (1–4), p  0.05 vs. baseline].
Furthermore, a nonsignificant trend toward increased
CFU-EC numbers at day 42 in nisoldipine-treated pa-
tients but not in patients treated with telmisartan alone
was observed [nisoldipine: 5 (2–37), p  0.094; com-
bination: 1.5 (1–4); p  0.058]. In a similar manner, the
number of CD133/CD34 cells showed a significant
increase at day 21 in patients receiving nisoldipine and
returned to nonsignificant levels at day 42 of treatment
(Fig. 1A). Importantly, numbers of circulating EPCs did
not show any correlation with clinical parameters, such
as BMI (data not shown) and blood pressure values, at
any time point (Fig. 2).
Phenotypic characterization of mobilized EPCs
Statistical analysis revealed a significant correlation
between the level of circulating CD133/CD34 cells
and the number of generated CFU-EC (rho  0.41; p 
0.05). To further identify the surface molecule expres-
sion pattern specific for functional EPCs, co-expres-
sion of the endothelial markers vWF, VE-cadherin
(CD144), CD31, and CD146 on the CD133/CD34
population was studied. As shown in Fig. 3, a strong
correlation between the number of CD133/CD34/
CD146 cells and the number of generated CFU-EC
(rho  0.93; p  0.0001) was discovered, indicating
that this subset represents functional EPCs. No corre-
lation was found between the number of CD133/
CD34 cells co-expressing either vWF, VE-cadherin,
or CD31 and the quantity of endothelial colonies (data
not shown).
FIG. 1. Mobilization of EPCs during antihypertensive treat-
ment as identified by FACS analysis and assessment of endo-
thelial colony formation. (A) The quantity of CD133/CD34
cells as revealed by flow cytometry is expressed as percentage
of total mononuclear blood cells. Values at baseline, after 21
days, and 42 days of antihypertensive treatment are given for the
different treatment groups. (B) Total numbers of CFU-EC gen-
erated from mononuclear blood cells in vitro at baseline, at day
21, and at day 42 of antihypertensive treatment are shown for the
different groups. Median, lower quartiles (Tukey’s hinges), and
extremes are given. *p  0.01 versus baseline levels in the nisol-
dipine group; †p  0.05 versus baseline levels in the nisoldipine
group; §p  0.05 versus baseline levels in the combination group.
showed no clinically relevant differences among treatment
groups. As shown in Table 2, mean blood pressure was
reduced in patients after 6 weeks of antihypertensive treat-
ment with telmisartan (7.0 mmHg; p  0.05) and the
combination of both substances (8.2 mmHg; p  0.05).
In patients treated with nisoldipine alone, a trend toward
lower blood pressure values was observed, but values
failed to reach statistical significance during the study pe-
riod (3.9 mmHg; p  0.090).
Mobilization of EPCs during 
antihypertensive treatment
To detect circulating EPCs, peripheral blood cells
were analyzed by flow cytometry for the presence of
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Morphological characteristics of 
in vitro-generated CFU-EC
Colonies grown in methylcellulose were not only eval-
uated for their number but also for their morphology.
With respect to the size, three different classes of CFU-
EC were discernible (Fig. 4). Most of the colonies con-
sisted of 20–100 loosely packed small-sized round cells.
In addition, intermediate-sized CFU-EC composed of up
to 500 cells and large-sized colonies comprising more
than 1000 cells were detected. These giant colonies were
exclusively observed in cultures derived from patients
treated with nisoldipine alone (n  5 patients).
DISCUSSION
The main findings of the present study are that: (1)
treatment with the calcium channel blocker nisoldipine
leads to a mobilization of EPCs in patients with essen-
tial hypertension, (2) mobilized EPCs display a CD133/
CD34/CD146 phenotype, and (3) in part possess the
capacity to generate extraordinary large-sized colonies.
In our study, EPCs were identified and quantified by
two methods. In one approach, EPCs were studied in a
clonogenic assay, which has been developed and estab-
lished in our laboratory (2). This assay has been shown
to reflect specifically the number of EPCs contained in
CD133 populations and the endothelial nature of the
resulting colony-forming units in this assay, so called
CFU-EC, has been proven by immunocytochemistry (2).
In parallel, FACS analysis was performed using fluo-
rochrome-conjugated antibodies against CD133 and
CD34, because EPCs have been shown to be contained
in the CD133/CD34 population of bone marrow and
FIG. 2. The number of endothelial colonies (CFU-EC) does not correlate significantly with blood pressure or blood pressure
reduction during antihypertensive treatment. (A) Correlation between the number of CFU-EC and mean arterial blood pressure
at baseline. (B) Correlation between the change in the number of CFU-EC and change in mean arterial blood pressure at day 21
of antihypertensive treatment. Correlations are given as Spearman’s rho, as indicated.
FIG. 3. Mobilized EPCs are characterized by a CD133/
CD34/CD146 phenotype. (A) Correlation between CFU-EC
and CD133/CD34/CD146 cells. Gray lines indicate 95%
confidence interval limits for the linear fit (black line). (B) Rep-
resentative two-color flow cytometry analysis of the peripheral
blood mononuclear cell fraction from a patient treated with
nisoldipine, quantifying co-expression of CD133, CD34, and
CD146.
A B
A
B
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mobilized peripheral blood (1,2). In this context, levels
of baseline and mobilized CD133/CD34 cells are con-
sistent with those observed in other clinical studies inves-
tigating EPC mobilization (12,24). Circulating CD133/
CD34 populations were then further analyzed for
coexpression of various endothelial markers, including
vWF, VE-cadherin, CD31, and CD146. Expression of
VEGFR-2 was not studied because reliable fluoro-
chrome-conjugated antibodies to this molecule were not
commercially available at the time when our study was
performed and indirect staining combined with direct
staining for two-color flow cytometry was found to yield
nonspecific results (unpublished observation). Interest-
ingly, by using these two methods, we found a remark-
able correlation between the number of CFU-EC gener-
ated in vitro and the number of CD133/CD34/CD146
cells in the circulation, suggesting that this phenotype de-
fines a specific subset of functional EPCs. This interpre-
tation is in line with a recent study by Delorme and col-
leagues, demonstrating that the CD146 population of
human peripheral blood not only comprises mature en-
dothelial cells but also contains a subset of functional
EPCs (25). Our interpretation gains further support by
the observation that the other subsets of circulating
CD133/CD34 cells detected in our study did not cor-
relate with the number of CFU-EC. Thus, our data might
add to the ongoing discussion whether CD146 might 
be a useful marker to determine biological activity of
EPCs (26).
Baseline numbers of in vitro-grown CFU-EC as well
as those of circulating CD133/CD34 cells showed a
considerable interpatient variation, a phenomenon that is
common in stem cell research (27). This fact together
with the relatively small number of patients enrolled in
the study contributed to the considerable level of vari-
ability in our data. Despite these limitations, we were able
to detect mobilization of EPCs in all patients receiving
nisoldipine (alone and in combination with telmisartan),
whereas treatment with telmisartan alone was found not
to influence the numbers of circulating EPCs. Further-
more, nisoldipine-induced mobilization of EPCs was
shown to peak at day 21 of treatment and a trend toward
elevated numbers of EPCs was observed even after 42
days of treatment. Additionally, nisoldipine treatment in-
duced a shift in the antigen expression of the mobilized
cells from a progenitor phenotype to a phenotype of ma-
ture endothelial cells (data not shown). This shift was de-
tectable at day 42 of the study and was associated with
the appearance of morphologically mature endothelial
cells in the colony assays (data not shown). Thus, nisol-
dipine may also favor accelerated differentiation of mo-
bilized EPCs toward mature endothelial cells, which then
might contribute to vessel repair and vasoprotection, re-
spectively, in hypertensive patients. Interestingly, induc-
tion of EPC mobilization followed by accelerated EPC
differentiation has also been demonstrated for growth
factors, such as VEGF, and statins (12,19).
In our study, telmisartan significantly lowered blood
pressure, whereas nisoldipine only induced a statistically
nonsignificant trend toward lower blood pressure. The
explanation for this observation remains unclear. Al-
though we cannot exclude that different blood pressure-
lowering effects of telmisartan and nisoldipine account
for different effects on EPC mobilization, neither base-
line levels of circulating EPCs nor numbers of mobilized
EPCs during treatment significantly correlated with mean
blood pressure levels or the extent of blood pressure re-
duction at any time point. Therefore, it is rather unlikely
that blood pressure reduction is considerably involved in
nisoldipine-mediated mobilization of EPCs.
The finding that three different sizes of CFU-EC were
distinguishable in our clonogenic assay suggests that mo-
bilized cells comprised EPCs with different clonogenic
and proliferative properties. In the hematopoietic system,
it is well established that on the basis of these properties,
a hierarchy of stem and progenitor cells exists (28). In
FIG. 4. Morphological characteristics of CFU-EC observed during antihypertensive treatment. Three different sizes of CFU-
EC were distinguishable, indicating different proliferative capacities of the mobilized EPCs. (A) Small-sized CFU-EC with 
typical morphology showing 20–100 loosely packed small round cells. (B) Intermediate-sized CFU-EC with typical morphology.
(C) Large-sized CFU-EC with typical morphology. Large-sized CFU-EC were exclusively generated from samples of patients
treated with nisoldipine alone. (Original magnification, 10.)
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this context, colony-forming cells with high proliferative
potential (HPP-CFC) have been defined by their ability
to form large colonies in vitro (approximately 5  104
cells/colony) (29). Recently, Ingram and colleagues re-
ported the identification of a similar hierarchy of EPCs
(11). They showed that human cord blood but not adult
peripheral blood contains a population of high prolifera-
tive potential-endothelial colony-forming cells (HPP-
ECFC), which gives rise to higher numbers and larger
sizes of colonies and at an earlier time point as compared
to adult peripheral blood EPCs. Upon replating, HPP-
ECFC had the capacity to generate secondary and tertiary
colonies. Additionally, HPP-ECFC-derived cells showed
a five-fold higher expansion potential than adult periph-
eral blood EPCs. Although we did not study the prolif-
erative capacity of the three different classes of colonies
and used different culture conditions for our colony as-
say, we hypothesize that the large-sized colonies ob-
served in our study are derived from HPP-ECFC, which
are mobilized from the bone marrow into the circulation.
Our findings seem to complement the study by Ingram
et al., in which HPP-ECFC could not be identified in
steady-state adult peripheral blood. Thus, certain condi-
tions that induce mobilization of EPCs in adult humans
might also lead to a release of HPP-ECFC into the cir-
culation. Besides, it is important to note that the colony
assay used in our study was developed in close analogy
to the standard methylcellulose-based colony assay for
hematopoietic stem and progenitor cells and, therefore,
might be ideal to investigate the full clonogenic poten-
tial of different populations of human EPCs.
Interestingly, large-sized CFU-EC consisting of more
than 1,000 cells were only observed in the nisoldipine
monotherapy group (5/13 patients), indicating that nisol-
dipine induces mobilization of HPP-ECFC, whereas
telmisartan (alone or combined with nisoldipine) might
interfere with this process. It is rather unlikely that nisol-
dipine itself increased the proliferative properties of mo-
bilized EPCs because also small- and intermediate-sized
colonies were observed during treatment with nisoldip-
ine. Mechanisms responsible for nisoldipine-induced mo-
bilization of EPCs remain speculative. A previous report
suggests that nisoldipine affects endothelial nitric oxide
(NO) bioavailability, a molecule that is known to play a
pivotal role in vascular integrity and, recently, has been
shown to be essential for EPC mobilization from the bone
marrow niche (30,31). Hence, nisoldipine-mediated in-
duction of NO bioavailability in the bone marrow niche
might account for increasing EPC numbers during anti-
hypertensive treatment with this compound. Second,
nisoldipine as well as other dihydropyridines have been
shown to induce microvascular permeability and subse-
quently to cause pretibial edema, a well-known side ef-
fect of dihydropyridines (32). Induction of microvascu-
lar permeability may also contribute to changes in the
bone marrow niche, e.g., extravasation of matrix-cleav-
ing enzymes, which may ultimately facilitate EPC mo-
bilization. Nevertheless, in our study, numbers of circu-
lating EPCs were not significantly higher in patients
developing pretibial edema during treatment with nisol-
dipine (4 patients; data not shown).
In contrast to nisoldipine treatment, treatment with
telmisartan did not significantly affect the total number
of circulating EPCs in the patients studied. Furthermore,
blood samples from telmisartan-treated patients (mono
and combination therapy) did not yield any giant CFU-
EC, as observed in patients treated with nisoldipine
alone, indicating that telmisartan attenuates nisoldipine-
induced mobilization of different population of EPCs.
These findings are in line with a recent study by Nick-
enig and colleagues, which showed that the number of
circulating EPCs inversely correlates with the intake of
AT1 receptor antagonists in patients with coronary heart
disease (33). In this regard, a negative effect of AT1 re-
ceptor antagonists on the expression and activity of
MMP-9 (gelatinase B) has been reported, a protease that
has been implicated in EPC mobilization from the bone
marrow niche (34,35). Hence, such potential telmisar-
tan-induced effects may be responsible for the absence
of HPP-ECFC in patients who received the combination
therapy. Conversely, Bahlmann and colleagues recently
reported that AT1 receptor antagonists induce mobi-
lization of circulating endothelial progenitor cells in pa-
tients with type 2 diabetes (36). The apparent discrep-
ancy with our findings is most likely due to differences
in the type of cells investigated as well as with differ-
ences in the disease studied. For identification of EPCs,
Bahlmann et al. placed the mononuclear cell fraction
from patients with type 2 diabetes in suspension culture
containing low concentrations of angiogenic factors and
analyzed the adherent cell fraction obtained after 7 days
for the number of Ac-DiI-LDL-uptake- and UEA-1-
binding-positive cells. Because Ac-DiI-LDL uptake and
UEA-1 binding represent functionalities commonly
shared by mature endothelial cells, it is impossible to
state whether the cells quantified in this study indeed
represented EPCs. Nevertheless, our data indicate that
treatment with telmisartan does not lead to an increase
in the number of circulating EPCs in patients with es-
sential hypertension.
In summary, we demonstrated that nisoldipine induces
mobilization of EPCs in hypertensive patients. This ef-
fect appeared to occur independently of the blood pres-
sure-lowering effect of this compound. Mobilized EPCs
were identified to display a CD133/CD34/CD146
phenotype. With respect to functional properties, a pro-
portion of the mobilized EPCs (exclusively mobilized in
the nisoldipine monotherapy group) had the capacity to
generate extraordinarily large-sized CFU-EC that to our
knowledge have not been described in adult humans be-
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fore. In conclusion, nisoldipine-induced EPC mobili-
zation in patients with essential hypertension might rep-
resent a novel mechanism by which this compound con-
tributes to vasoprotection in hypertensive patients.
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